MedTrace Logo

Hematopoietic Cell Transplantation for Patients With Hematologic Malignancies Using Related, HLA-Haploidentical Donors

NCT01374841 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2023-06-28

No results posted yet for this study

Summary

The purpose of this study is to determine if engraftment can be achieved safely in patients with high-risk hematologic malignancies who undergo non-myeloablative transplant with peripheral stem cells from Human Leukocyte Antigen (HLA) haploidentical donors with pre and post-transplant cyclophosphamide as immunosuppression.

Conditions

  • Hematologic Neoplasms

Interventions

DRUG

Cyclophosphamide

14.5 mg/kg, IV qd on day -6 and -5 and 50 mg/kg, IV on day +3 and +4

OTHER

Hematopoietic Stem Cell Transplantation,

Hematopoietic Stem Cell Transplantation,

Sponsors & Collaborators

  • European Institute of Oncology

    lead OTHER

Principal Investigators

  • Rocco Pastano, MD · European Institute of Oncology

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-08-31
Primary Completion
2023-12-31
Completion
2023-12-31

Countries

  • Italy

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01374841 on ClinicalTrials.gov